13F Holdings
中文EN

DFTX Definium Therapeutics, Inc.

Medicinal Chemicals & Botanical Products · Nasdaq · SEC CIK 1813814 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-100.8%
TTM EPS YoY-47.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-61.4%
ROA-51.5%
ROIC (approx.)-43.9%
Asset turnover—

Leverage & solvency

Liabilities / assets9.9%
Debt / equity0.04x
Current ratio15.53x
Interest coverage-51.91x

Cash quality & payout

Operating cash flow / net income0.57x
Accruals ratio-22.3%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue—————
R&D expense$117.67M$65.30M$52.12M$36.17M$34.79M
SG&A expense$48.64M$38.62M$41.74M$30.16M$59.06M
Operating income-$166.31M-$103.92M-$93.87M-$66.33M-$93.85M
Interest expense$5.48M$2.28M$920,000——
Pretax income-$183.79M-$108.68M-$95.73M-$56.80M-$94.19M
Income tax$0———-$1.16M
Net income-$183.79M-$108.68M-$95.73M-$56.80M-$93.04M
EPS (basic)-2.06-1.54-2.44-1.84-3.40
EPS (diluted)-2.06-1.54-2.44-1.84-3.40
Weighted avg. shares (diluted)89.33M70.46M39.16M30.86M27.38M
Banking
Net interest income——$4.66M$1.50M-$359,000
Balance sheet
Cash & equivalents$257.84M$273.74M$99.70M$142.14M$133.54M
Short-term investments$153.76M$0———
Current assets$419.32M$281.62M$103.87M$146.06M$137.22M
Goodwill$19.92M$19.92M$19.92M$19.92M$19.92M
Intangibles—$0$527,000$3.69M$6.87M
Total assets$440.10M$302.15M$124.54M$169.99M$164.00M
Current liabilities$66.70M$38.85M$32.25M$17.89M$10.41M
Long-term debt$40.58M$21.85M$14.13M——
Total debt$40.58M$21.85M$14.13M——
Total liabilities$107.77M$60.70M$46.41M$19.08M$12.34M
Shareholders' equity$332.33M$241.45M$78.13M$150.92M$151.66M
Net debt-$217.26M-$251.89M-$85.58M——
Shares outstanding98.78M75.10M41.10M37.98M28.13M
Cash flow statement
Operating cash flow-$131.56M-$79.13M-$64.36M-$50.14M-$45.82M
Investing cash flow-$151.61M$0——-$297,000
Financing cash flow$267.27M$253.20M$21.85M$59.05M$98.82M
Stock-based compensation$20.10M$16.91M$15.18M$13.71M$42.72M

Free plan shows the latest 5 periods; Pro shows all 7 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.